Trappe H J, Wenzlaff P, Pfitzner P, Fieguth H G
Department of Cardiology and Angiology, University Hospital Herne, Ruhr University Bochum, Germany.
Heart. 1997 Sep;78(3):243-9. doi: 10.1136/hrt.78.3.243.
To determine whether patients with life threatening ventricular tachyarrhythmias, impaired left ventricular function, and severe heart failure will benefit from implantable cardioverter-defibrillator (ICD) treatment.
410 patients were followed up after ICD implant. Left ventricular function was assessed by the New York Heart Association (NYHA) functional class of heart failure: 50 patients (12%) were in NYHA I-II, 151 (37%) in NYHA II, 117 (29%) in NYHA II-III, and 92 (22%) in NYHA III. Epicardial ICD implantation was performed in 209 patients (51%) and 201 patients (49%) received non-thoracotomy ICDs.
Perioperatively, 12 patients (3%) died, more often after epicardial ICD implant (11/209 patients, 5%) than after transvenous implant (1/201 patients, < 1%) (P < 0.05). During a mean (SD) follow up of 28 (24) months (range < 1 to 114 months), 90 patients (23%) died: nine (2%) died from sudden arrhythmia; five (1%) also died suddenly but probably not from arrhythmic causes; 55 (14%) died from cardiac causes (congestive heart failure, myocardial reinfarction); 21 (5%) died from non-cardiac causes. The three year, five year, and seven year survival was 92-96% for arrhythmic mortality in NYHA class I, II and III, compared to a three year survival of 94% and a five year and seven year survival of 84% for patients in NYHA class II-III. 338 patients (82%) received ICD shocks (21 (SD 43) shocks per patient); patients in NYHA class II (83%), class II-III (84%), and class III (90%) received ICD discharges more often than those in class I-II (64%) (P < 0.05). The mean (SD) time interval between ICD implant and the first ICD shock was shorter in NYHA class II (16 (17) months), class II-III (19 (27) months), and class III (16 (19) months) than in class 0-I (22 (24) months) (P < 0.05).
Patients with mild, moderate, and severe left ventricular dysfunction benefit from ICD treatment and these patients survive for a considerable time after the first shock. Survival is influenced by the degree of left ventricular dysfunction; aggressive treatment of heart failure is necessary as well as ICD therapy.
确定患有危及生命的室性快速心律失常、左心室功能受损和严重心力衰竭的患者是否能从植入式心脏复律除颤器(ICD)治疗中获益。
对410例植入ICD后的患者进行随访。通过纽约心脏协会(NYHA)心力衰竭功能分级评估左心室功能:50例患者(12%)为NYHA I-II级,151例(37%)为NYHA II级,117例(29%)为NYHA II-III级,92例(22%)为NYHA III级。209例患者(51%)接受了心外膜ICD植入,201例患者(49%)接受了非开胸ICD植入。
围手术期,12例患者(3%)死亡,心外膜ICD植入后死亡的情况更为常见(209例患者中有11例,5%),高于经静脉植入后(201例患者中有1例,<1%)(P<0.05)。在平均(标准差)28(24)个月的随访期内(范围<1至114个月),90例患者(23%)死亡:9例(2%)死于心律失常性猝死;5例(1%)也突然死亡,但可能并非由心律失常原因导致;55例(14%)死于心脏原因(充血性心力衰竭、心肌再梗死);21例(5%)死于非心脏原因。NYHA I级、II级和III级患者心律失常性死亡的三年、五年和七年生存率为92%-96%,相比之下,NYHA II-III级患者的三年生存率为94%,五年和七年生存率为84%。338例患者(82%)接受了ICD电击(每位患者平均[标准差]21[43]次电击);NYHA II级(83%)、II-III级(84%)和III级(90%)的患者比I-II级(64%)的患者更频繁地接受ICD放电(P<0.05)。NYHA II级(16[17]个月)、II-III级(19[27]个月)和III级(16[19]个月)患者从ICD植入到首次ICD电击的平均(标准差)时间间隔比0-I级(22[24]个月)更短(P<0.05)。
轻度、中度和重度左心室功能障碍患者可从ICD治疗中获益,且这些患者在首次电击后能存活相当长的时间。生存率受左心室功能障碍程度的影响;除了ICD治疗外,积极治疗心力衰竭也很有必要。